Tempest Therapeutics (TPST) - Uzoq muddatli qarzning kapitalga nisbati
Tempest Therapeutics (TPST) ishlab chiqarish va sinovlar uchun autsorsingga tayanadi, bu esa uning ilmiy jamoasining moslashuvchanligini ta'minlaydi. Ushbu uzoq muddatli qarzning kapitalga nisbati grafigi moliyaviy leverajni namoyish etadi va ushbu ko'rsatkich 0.00 darajasida saqlanmoqda. Biznes iqtisodiy sikllardan mustaqil bo'lib, jigar saratoni uchun maqsadli terapiyalarning ishlab chiqilishi kompaniyaga faol o'sish bosqichini taqdim etadi.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_TPST_-_Tempest-Therapeutics_-_Long-Term-Debt-to-Equity "tempesttx.com (TPST): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi 04.07.2022dan 29.10.2026gacha | 👁️GURU.Markets👁️")
Tempest Therapeutics kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Tempest Therapeutics|TPST - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati tempesttx.com|TPST - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Tempest Therapeutics, Inc.|TPST - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Tempest Therapeutics
Kompaniyaning umumiy tahlili:Tempest Therapeutics Inc - TPST
Ushbu koeffitsiyent kompaniyaning uzoq muddatli to'lov muddatiga ega qarz kapitaliga qanchalik bog'liqligini belgilaydi. Algoritm moliyaviy barqarorlikni baholash uchun uzoq muddatli kreditlar hajmini o'z kapitali miqdori bilan solishtiradi. Uzoq muddatli majburiyatlarning kapitalga nisbatini tahlil qilish orqali investor haddan tashqari qarz yuklamasi xatarlarini aniqlaydi. Tempest Therapeutics (TPST) uchun ushbu muvozanat laboratoriyaning doimiy xarajatlarini qoplash uchun juda muhimdir. Past leveraj royalti evaziga tijoratlashtirishni hamkorlarga topshirish strategiyasining hayotiyligini tasdiqlaydi.
Muhim raqobatchilar
Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati Ascentage Pharma Group AAPG|CGON: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|UroGen Pharma - Uzoq muddatli qarzning kapitalga nisbati|Bicara Therapeutics Inc (BCAX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|PSNL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Erasca Oncology (ERAS)|Uzoq muddatli qarzning o'z kapitaliga nisbati Delcath Systems, Inc.|YMAB: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati AURA (Aura Biosciences)|CADL (candeltx.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati ARAY (Accuray Inc.)|SLS - Uzoq muddatli qarzning o'z kapitaliga nisbati|ACTU: Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR - Uzoq muddatli qarzning kapitalga nisbati|tuhurabio.com (HURA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Protara Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|FATE (Fate Therapeutics Corp) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Aadi Bio WHWK|Uzoq muddatli qarzning o'z kapitaliga nisbati TCRX (TScan Therapeutics)|Uzoq muddatli kreditlarning kapitalga nisbati CSBR|Uzoq muddatli qarzning kapitalga nisbati XBIT (XBiotech)|CEL-SCI Corp. (CVM) - Uzoq muddatli majburiyatlarning kapitalga nisbati|OSTX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Radiopharm Theranostics Ltd (RADX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|artivabio.com (ARTV) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati ANL (Adlai Nortye)|VERU (Veru) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Xilio XLO|Uzoq muddatli qarzning o'z kapitaliga nisbati Renovaro Inc. (RENB)|Uzoq muddatli qarzdorlikning kapitalga nisbati muraloncology.com|Kairos Pharma - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli kreditlarning kapitalga nisbati OKUR (OnKure Therapeutics, Inc.)|GDTC: Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti CRIS (Curis, Inc.)|APLM (apollomicsinc.com) - Uzoq muddatli qarzning o'z kapitaliga nisbati|THAR: Uzoq muddatli kreditlarning kapitalga nisbati|ADVB (Advanced Biomed Inc.) - Uzoq muddatli qarzning kapitalga nisbati|GNPX: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati CLDI|SBFM - Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Xenetic Biosciences, Inc. XBIO|Uzoq muddatli qarzning kapitalga koeffitsiyenti SLRX|Purple Biotech - Uzoq muddatli qarzning kapitalga nisbati|AONC - Uzoq muddatli qarzning kapitalga nisbati|BeiGene (BGNE) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati CKPT (Checkpoint Therapeutics Inc.)|ELEV (Elevation Oncology, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati iCAD Corp ICAD|Uzoq muddatli qarzning o'z kapitaliga nisbati IKNA (Ikena Oncology, Inc.)|Uzoq muddatli qarzning kapitalga nisbati notablelabs.com (NTBL)|Viracta Therapeutics, Inc. - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli kreditlarning kapitalga nisbati MOR (MorphoSys Inc)|NAYA Bio - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Ascentage AAPGV